Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bullish +65

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now? - Zacks Investment Research

📉 Stock Performance: ZBH shares dropped 22% in the past year, significantly outperforming the industry's 20.5% fall and the S&P 500's 18.3% growth.

💰 Valuation Metrics: The company boasts a market cap of $17.18 billion and an earnings yield of 9.6%, compared to the industry average of 2.6%.

📈 Earnings Consistency: Zimmer Biomet has beaten estimates in each of the trailing four quarters with an average surprise of 2.53%.

🤖 Robotics Expansion: The acquisition of Monogram Technologies adds robotic technologies expected to commercialize with implants in early 2027.

🦵 Knee Business Growth: Q4 2025 U.S. knee revenues grew 6% YoY, driven by cementless offerings like Persona OsseoTi and Oxford Partial Cementless Knee.

📊 Cementless Penetration: The Persona OsseoTi ended 2025 at approximately 35% penetration of U.S. total knee implants, showing continued acceleration.

🌍 Revenue Stability: Despite pricing pressure, the company delivered 5.4% organic constant currency revenue growth globally in Q4 2025.

🇺🇸 Regional Performance: U.S. growth was 5.7% while international growth was 5% in Q4 2025, with variable international performance quarter to quarter.

⚔️ Competitive Landscape: The orthopedic market is highly competitive against major rivals including Stryker, J&J DePuy, Smith & Nephew, and Medtronic.

📅 2026 Outlook: Consensus revenue estimates for 2026 are pegged at $8.55 billion, representing a 3.9% rise from the prior year.

🔬 Innovation Focus: The company maintains a long-term objective to drive cementless penetration higher through training expansion and competitive conversions.

📉 Zacks Rank: The stock currently carries a Zacks Rank #3 (Hold) classification.

Bullish Signals
  • Zimmer Biomet has significantly outperformed the broader market, dropping only 22% while the industry fell 20.5% and the S&P 500 grew 18.3% over the past year.
  • The company's earnings yield of 9.6% is substantially higher than the industry average of 2.6%, indicating strong profitability relative to peers.
  • Zimmer Biomet has a perfect track record of beating earnings estimates for the trailing four quarters with an average surprise of 2.53%.
  • Recent acquisition of Monogram Technologies expands the robotics portfolio, adding surgeon-guided technologies expected to commercialize in early 2027.
  • The Knee business is accelerating growth with U.S. revenues up 6% year over year in Q4 2025, driven by strong uptake of cementless offerings.
  • Cementless implant penetration reached approximately 35% of total knee implants at the end of 2025, reflecting continued acceleration from prior levels.
  • Organic constant currency revenue growth was positive across all regions in Q4 2025, with global growth of 5.4%, U.S. growth of 5.7%, and international growth of 5%.
  • The Oxford Partial Cementless Knee continues to outperform expectations with high post-training adoption rates and solid competitive account wins.
  • Management highlights steady demand trends across key regions supported by healthy end markets and improved procedure volumes through 2025.
  • Analysts project a 3.9% revenue increase for 2026, with consensus estimates pegged at $8.55 billion.
Risk Factors
  • The orthopedic industry is intensely competitive with numerous large players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic.
  • To maintain market share, Zimmer Biomet faces the ongoing challenge of constantly introducing or acquiring new products to withstand competitive pressure.
  • International performance has remained somewhat variable on a quarter-to-quarter basis despite steady demand trends in key regions.
  • Pricing pressure continues to be an ongoing factor affecting the global musculoskeletal market environment.
  • The stock carries a Zacks Rank #3 (Hold), suggesting analysts do not currently view it as a strong buy compared to other opportunities.
Full Analysis
Zimmer Biomet (ZBH) has dropped 22% over the past year, significantly outperforming the industry's 20.5% decline and the S&P 500's 18.3% growth. The company holds a Zacks Rank #3 (Hold) with a market capitalization of $17.18 billion. Notably, its earnings yield stands at 9.6%, which is well ahead of the industry average of 2.6%. Zimmer Biomet has surpassed earnings estimates for each of the trailing four quarters, delivering an average surprise of 2.53%. Under a strategy of innovation and diversification, the company recently acquired Monogram Technologies to expand its robotics portfolio with semi-autonomous technologies expected to commercialize in early 2027. The firm continues to focus on accelerating growth within its Knee business, driven by the adoption of cementless offerings like the Persona OsseoTi and Oxford Partial Cementless Knee. In the fourth quarter of 2025, U.S. knee revenues grew 6% year over year, supported by robust uptake of these new products. Despite ongoing pricing pressure, Zimmer Biomet reported stability in the global musculoskeletal market through 2025, aided by healthy end markets and improved procedure volumes. The company achieved organic constant currency revenue growth of 5.4% globally in Q4 2025, with U.S. growth at 5.7% and international growth at 5%. Management highlighted steady demand trends across key regions, though international performance remained somewhat variable quarter to quarter. The competitive landscape remains intense with major players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic. To maintain market share, Zimmer Biomet must continuously introduce or acquire new products. Analysts peg the consensus estimate for 2026 revenues at $8.55 billion, suggesting a 3.9% rise from the year-ago reported number.